Company Interview / Pain relief as AFT Pharma reports record revenue

AFT Pharmaceuticals (ASX:AFP) has reported record FY25 revenue at $208M NZD, marking 6% growth. CEO of AFT Pharma, Hartley Atkinson notes revenue growth is driven by Australasian performance and recovery in Asia. Net profit falls to $12M due to heavy investment in new branches and R&D, though the focus remains on hitting $300M by FY27.

Hartley highlights the global launch of Maxigesic tablets as an opioid alternative, addressing pain management in markets like the US, UK, and Australia. AFT is working on 13 R&D projects, including an injectable iron product at phase three clinical trial.The company aims to commercialise five new products to fuel growth.

Despite increased investment, AFT decreases net debt to $14.5M, doubling dividends and funding expansion from existing profits. Hartley discussed a diversified market approach to mitigate tariff impacts, with strong focus on China, Middle East, and Europe. AFT aims for significant growth and market expansion over the next five years.